Endra Life Sciences ( (NDRA) ) has released its Q3 earnings. Here is a breakdown of the information Endra Life Sciences presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ENDRA Life Sciences Inc. is a medical technology company focused on developing devices for liver fat measurement, primarily serving the healthcare sector with innovative solutions for metabolic disease detection. The company recently released its earnings report for the quarter ending September 30, 2025, highlighting significant financial metrics and strategic developments. ENDRA reported a net loss of $1.6 million for the quarter, a decrease from the $2.4 million loss in the same period last year. The company’s operating expenses also saw a reduction, with research and development costs dropping significantly. Despite the financial losses, ENDRA continues to pursue its strategic initiatives, including the development of its liver fat measurement device and the adoption of a digital asset treasury strategy. Looking ahead, ENDRA’s management remains focused on securing additional financing to support its operations and achieve profitability, while continuing to innovate in the medical technology space.